scholarly journals Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE

Cancer ◽  
2018 ◽  
Vol 124 (8) ◽  
pp. 1722-1732 ◽  
Author(s):  
Elias J. Jabbour ◽  
Daniel J. DeAngelo ◽  
Matthias Stelljes ◽  
Wendy Stock ◽  
Michaela Liedtke ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Safety Analysis ◽  
Efficacy And Safety ◽  
Inotuzumab Ozogamicin ◽  
Age Cohort

scholarly journals Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

2020 ◽  
Vol 28 (1) ◽  
pp. 252-259
Author(s):  
Warren Fingrut ◽  
Wendy Davis ◽  
Eric McGinnis ◽  
Karen Dallas ◽  
Khaled Ramadan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Monoclonal Antibody ◽  
Flow Cytometry ◽  
Acute Lymphoblastic Leukemia ◽  
Survival Benefit ◽  
Lymphoblastic Leukemia ◽  
Surface Expression ◽  
Inotuzumab Ozogamicin ◽  
Cell Acute Lymphoblastic Leukemia

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.

Sign in / Sign up

Export Citation Format

Share Document